Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Take the Money and Run -- Ignore unavailable to you. Want to Upgrade?

To: Jorj X Mckie who wrote (4821)	6/21/2002 11:28:08 AM
From: quote 007	Read Replies (2) \| Respond to of 17639

thats all i use is piff charts--3 letters are tough--i also am short bsc nke lxk--and they are slowwwwwwww--

To: Jorj X Mckie who wrote (4821)	6/21/2002 11:37:03 AM
From: Dave Gore	Respond to of 17639

edit out - see next post.

To: Jorj X Mckie who wrote (4821)	6/21/2002 11:37:14 AM
From: Dave Gore	Read Replies (1) \| Respond to of 17639

KG ALERT --- I checked their filing and Levoxyl is only 15.4% of their sales. Yet stock is down about 27% over the last few days and 22% since the rumor started yesterday. Here's my thinking: Even if the worst case scenario happened and King got zero sales from Levoxyl in the future, the stock is still down too much, by my calculations. Plus the company says the patent is safe, if I am not mistaken. Looks like Shorts first targeted Altace with nasty, untrue rumors and now they picked on Levoxyl. Undoubtedly the company will have a PR out soon. Shorts know in this market you just need to say something scary and the Market will always react violently by selling, not because they necessarily believe the rumors, but because they think they need to sell first before the next guy. What a sinister game! I don't mind "shorts", I mind crooked "shorts" or crooked "hypes". From their filing: Altace(R) accounted for approximately 38.6% and Levoxyl(R) accounted for approximately 15.4% of our net sales for the three months ended March 31, 2002, and Altace(R), Levoxyl(R), Thrombin-JMI(R), Lorabid(R), Bicillin(R) and royalty revenues collectively accounted for approximately 77.8% of our net sales during the same period. We believe that sales of these products will continue to constitute a significant portion of our total revenues for the foreseeable future. Accordingly, any factor adversely affecting sales of any of these products or products for which we receive royalty payments could have a material adverse effect on our business, financial condition, results of operations and cash flows.